Global Home Infusion Therapy Market Size, Share & Forecast 2026-2033

Overview

Global Home Infusion Therapy Market size was valued at USD 42.6 billion in 2025 and is expected to reach USD 78.3 billion by 2033, growing with a CAGR of 7.9% during the forecast period 2026-2033. The increasing incidence of chronic conditions is a major driver of growth in the home infusion therapy market because many long-term diseases require ongoing, controlled administration of medications that cannot be effectively delivered through oral routes.

Conditions such as cancer, diabetes, autoimmune disorders, gastrointestinal diseases, and neurological disorders often depend on intravenous therapies, including biologics, chemotherapy, immunoglobulins, and pain management drugs. As the global burden of chronic diseases continues to rise, healthcare systems are increasingly relying on infusion therapies to manage complex treatment regimens, improve patient outcomes, and reduce disease progression. This growing clinical need is directly expanding the demand for infusion devices, consumables, and related healthcare services.

The scale of this rising disease burden further reinforces market growth. According to research published in The Lancet Oncology, the global cancer burden is expected to increase by more than 75% by 2030, significantly increasing the need for chemotherapy and supportive infusion-based treatments. Additionally, the International Diabetes Federation (IDF) reported that approximately 589 million adults were living with diabetes in 2021, a figure projected to rise to 853 million by 2050, further driving demand for insulin infusion therapies and related drug delivery systems. In response to this growing need, companies are advancing safer and more precise infusion technologies. In April 2024, Baxter International Inc. received U.S. FDA 510(k) clearance for its Novum IQ Large Volume Infusion Pump integrated with Dose IQ Safety Software, strengthening its portfolio of smart and accurate infusion solutions. Such innovations are enhancing treatment safety and efficiency, supporting the expanding adoption of infusion therapy across chronic disease management.

Drivers

Rapid Adoption of Smart Pumps, Digital Workflow Automation and Decision-Support Integration, EMR Connectivity, and Personalized Care Models

The rapid adoption of smart pumps, digital workflow automation and decision-support integration, EMR connectivity, and personalized care models is significantly accelerating the growth of the home infusion therapy market by improving safety, efficiency, and patient outcomes. Smart infusion pumps reduce medication errors through automated dose calculations, drug libraries, and real-time monitoring, while EMR-integrated systems ensure seamless data exchange between devices and electronic health records. This interoperability enhances clinical decision-making, reduces manual documentation errors, and streamlines workflow efficiency for healthcare providers. As healthcare systems increasingly prioritize precision and patient safety, these technologies are becoming essential components of modern infusion therapy delivery in both hospital and home-care settings.

Real-world advancements demonstrate how digital integration is transforming infusion care delivery. In April 2024, Becton Dickinson (BD) deployed BD Alaris EMR interoperability technology at Mackenzie Health, enabling two-way communication between IV pumps and electronic medical records. This innovation automated pump programming and reduced keystrokes by 86%, significantly lowering the risk of human error and improving clinical efficiency. Similarly, in March 2025, Uptiv Health partnered with Lamar Health to automate referral intake and prior authorization processes, reducing time-to-treatment for patients requiring infusion therapies. Together, these developments highlight how AI automation, smart connectivity, and personalized care models are streamlining operations and expanding access to infusion therapy, thereby driving strong market growth.

Cost-Effectiveness of Home Infusion Therapy

The cost-effectiveness of home infusion therapy is a major driver of growth in the home infusion therapy market, as healthcare systems increasingly seek to reduce the financial burden associated with inpatient and hospital-based care. Home infusion therapy allows patients to receive complex intravenous treatments such as antibiotics, chemotherapy, nutrition support, and pain management in the comfort of their homes, while significantly lowering overall treatment costs. This model reduces hospital bed occupancy, minimizes facility-related expenses, and improves resource allocation within healthcare systems. At the same time, patients benefit from greater convenience and reduced indirect costs such as travel and caregiver burden, making home-based care an attractive alternative to traditional hospital stays.

The cost advantage of home infusion therapy compared to inpatient care strongly reinforces its adoption across healthcare settings. According to the National Home Infusion Association (NHIA), home infusion therapy costs approximately USD 122 to USD 225 per day, whereas inpatient hospital care can range from USD 586 to USD 798 per day depending on the treatment required. This substantial cost differential highlights the economic incentive for insurers, providers, and patients to shift toward home-based treatment models. As healthcare systems continue to focus on value-based care and cost containment, the affordability and efficiency of home infusion therapy are expected to significantly drive market expansion.

Home Infusion Therapy Market Trends & Opportunities

Expansion of Telehealth

The expansion of telehealth market is emerging as a key trend in the home infusion therapy market by enabling remote patient monitoring, virtual clinical consultations, and timely management of infusion therapies outside traditional healthcare settings. Telehealth platforms improve access to care, reduce the need for hospital visits, and allow healthcare providers to monitor treatment adherence, manage complications, and adjust therapy plans in real time, thereby enhancing patient outcomes and supporting the shift toward home-based care. This integration of digital health technologies is particularly beneficial for patients requiring long-term infusion therapies for chronic diseases, infections, and specialty treatments. Reflecting this trend, in June 2024, MetroHealth and MUSC Health launched the first virtual telehealth company, a platform designed to improve patient access by combining digital tools with existing health system networks. Such innovations are accelerating the adoption of home infusion therapy by making care more accessible, coordinated, and patient-centric.

Adoption of Multi-Therapy Infusion Platforms

The adoption of multi-therapy infusion platforms is emerging as a key trend in the home infusion therapy market as healthcare providers seek versatile, patient-centric systems capable of administering multiple therapies through a single device while improving safety, efficiency, and ease of use. These advanced platforms support a wide range of infusion treatments, reduce the need for multiple specialized devices, and incorporate digital features such as programmable drug libraries, customized treatment protocols, and medication safety software to minimize errors and streamline clinical workflows. This trend reflects the growing demand for integrated home care solutions that enable personalized therapy and support the shift away from hospital-based treatment. A notable example is the May 2024 U.S. Food and Drug Administration (FDA) 510(k) clearance granted to Moog Inc. for its CURLIN 8000 Ambulatory Infusion System, a multi-therapy platform specifically designed for home infusion. The system combines precise infusion delivery with integration into the CURLIN RxManager medication safety software, allowing pharmacists to create customized pump configurations, drug libraries, clinical advisories, and patient-specific protocols, thereby enhancing treatment accuracy, workflow efficiency, and the overall quality of home infusion care.

Restraint

Limited Availability of Skilled Caregivers and Inadequate Supporting Infrastructure

Limited availability of skilled caregivers and inadequate supporting infrastructure act as a significant restraint on the home infusion therapy market because these services depend heavily on trained professionals to ensure safe and accurate drug administration outside hospital settings. Home infusion therapy requires expertise in intravenous catheter care, infusion pump setup, dosage programming, infection control, and emergency response in case of adverse reactions. However, shortages of qualified nurses, pharmacists, and home healthcare specialists limit the ability of providers to scale services, particularly for complex therapies such as chemotherapy, parenteral nutrition, and biologics. This constraint reduces patient access and slows the shift from hospital-based care to home-based treatment models.

Infrastructure limitations further restrict market expansion by affecting the reliability and reach of home infusion services. Effective home infusion care depends on coordinated logistics systems, cold chain management for temperature-sensitive drugs, infusion device availability, and rapid technical support in case of equipment malfunction. In many regions, especially rural and underserved areas, these systems are either underdeveloped or inconsistently available, making it difficult to ensure continuous and high-quality care delivery. As a result, even though demand for home-based treatment is increasing due to its cost-effectiveness and convenience, the lack of skilled caregivers and robust infrastructure continues to constrain the growth of the home infusion therapy market.

Segment Analysis

The global home infusion therapy industry is segmented based on product, application, end user region.

Increasing Demand for Infusion Pumps

Infusion pumps segment held a market revenue share of more than 47.6% in the year 2025. The infusion pumps segment is growing in the home infusion therapy market due to increasing demand for safe, accurate, and user-friendly drug delivery systems that enable patients to receive long-term treatment outside hospital settings. The rising prevalence of chronic diseases, including diabetes, cancer, and autoimmune disorders, is driving the adoption of advanced infusion pumps that improve dosing precision, enhance patient mobility, and support remote, home-based care. Technological innovations such as wearable, tubeless, and connected infusion devices are further expanding the use of infusion pumps by improving convenience, reducing treatment complexity, and encouraging greater patient adherence.

Reflecting this trend, in June 2026, Modular Medical commercially launched its Pivot tubeless insulin patch pump after receiving U.S. Food and Drug Administration (FDA) 510(k) clearance in April 2026. The fully electronic, wearable device features a removable two-part design, a 3 mL reservoir, an intuitive interface, and a flexible form factor that supports everyday activities while maintaining clinical accuracy and connectivity. By offering a simpler and more affordable alternative for patients transitioning from multiple daily injections, the Pivot system exemplifies how innovation in infusion pump technology is driving growth in the home infusion therapy market.

Chemotherapy/Oncology is the Fastest-Growing Application

The chemotherapy/oncology segment is growing in the home infusion therapy market due to the increasing adoption of patient-centric cancer care models that reduce hospital visits while maintaining effective treatment outcomes. Advances in oncology drug formulations, including subcutaneous therapies and simplified administration methods, are enabling more cancer treatments to be delivered in outpatient and home-based settings, improving patient convenience, reducing healthcare resource utilization, and enhancing quality of life. This trend is particularly important for patients with advanced cancers who require frequent, long-term therapy and benefit from minimizing the physical and emotional burden of repeated hospital visits. Reflecting this shift, in June 2026, Roche received approval from the Drugs Controller General of India (DCGI) for a subcutaneous formulation of atezolizumab (Tecentriq) for advanced lung cancer, reducing treatment administration time from several hours of intravenous infusion to approximately seven minutes while maintaining comparable clinical efficacy. This innovation demonstrates how streamlined oncology therapies are supporting the transition toward home- and outpatient-based infusion care, driving growth in the chemotherapy/oncology segment of the home infusion therapy market.

Home-Care segment is the Fastest-Growing End User

The home-care segment is growing in the home infusion therapy market due to increasing demand for cost-effective, patient-centered healthcare that enables individuals to receive complex intravenous treatments in the comfort of their homes. Rising prevalence of chronic diseases, an aging population, and the need to reduce hospital admissions are accelerating the shift toward home-based infusion services, which improve patient convenience, treatment adherence, and quality of life while lowering healthcare costs. Supportive reimbursement policies and government initiatives are also strengthening the adoption of home infusion care. A notable example is the March 2025 reintroduction of the Preserving Patient Access to Home Infusion Act in the United States, which aims to protect Medicare beneficiaries' access to home IV therapy by improving reimbursement and ensuring the continued availability of home infusion services. Such policy initiatives are expected to expand access to home-based treatment, encourage provider participation, and further drive the growth of the home-care segment within the home infusion therapy market.

Geographical Penetration

Rising Prevalence of Chronic Diseases in North America

North America held the largest market revenue share of 49% in the year 2025. The home infusion therapy market in North America is growing due to the rising prevalence of chronic diseases, a rapidly aging population, and increasing demand for cost-effective healthcare delivered outside traditional hospital settings. According to the Population Reference Bureau (January 2024), the U.S. population aged 65 years and older is projected to increase from 58 million in 2022 to 82 million by 2050, significantly expanding the population requiring long-term infusion therapies for conditions such as diabetes, cancer, autoimmune disorders, and infections. Similarly, in Canada, the Public Health Agency of Canada (PHAC) estimated in June 2024 that nearly half of adults aged 20 years and older have at least one of ten common chronic conditions, further driving demand for home-based infusion services that improve patient convenience while reducing healthcare costs.

The region is also benefiting from expanding outpatient care infrastructure and strategic collaborations that improve access to home infusion services. According to a June 2024 U.S. News & World Report survey, 94.8% of patients said they would recommend ambulatory surgery centers (ASCs), and the number of Medicare-certified ASCs in the United States increased to approximately 6,223 in 2024 from 5,000 in 2010, reflecting the continued shift toward outpatient healthcare delivery. Supporting this transition, in January 2024, BrightStar Care partnered with Paragon Healthcare to expand high-quality home infusion services across the United States. These developments are strengthening home-based care networks, improving patient access to infusion therapies, and contributing to the continued growth of the North American home infusion therapy market.

Europe Home Infusion Therapy Market: Rising Demand for Healthcare Services that Reduce Hospital Stays

The home infusion therapy market in Europe is growing due to the increasing prevalence of chronic diseases, an aging population, and the rising demand for healthcare services that reduce hospital stays while improving patient convenience and treatment outcomes. The growing burden of metabolic disorders and cancer is creating sustained demand for long-term infusion therapies that can be safely administered at home. For example, researchers at the German Diabetes Center (DDZ) estimate that up to 12 million people in Germany could be living with metabolic disorders by 2040. Similarly, a survey by Macmillan Cancer Support estimated that more than 3 million people were living with cancer in the United Kingdom in 2020, with that figure expected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. These trends are accelerating the adoption of home infusion therapy as healthcare systems seek more efficient ways to manage long-term treatment for chronic conditions.

Technological advancements in infusion devices are also supporting market growth by making home-based treatment safer, more accurate, and easier for both patients and healthcare providers. In May 2025, Penlon introduced a new range of infusion systems, including the HP TCi Syringe Pump with an intuitive 3.0-inch touchscreen interface and advanced target-controlled infusion (TCi) models such as Eleveld, designed to improve dosing accuracy and simplify clinical workflows. Alongside systems such as SYS-56 and SYS-70, these next-generation infusion pumps provide reliable infusion control and broad rate variability, enabling safer transitions from hospital-based care to home care environments. Such innovations are enhancing the quality and accessibility of home infusion therapy, further driving market growth across Europe.

Asia-Pacific Home Infusion Therapy: Driven by Investments in Healthcare Infrastructure, Training, and Medical Device Manufacturing Across the Region

Asia-Pacific is the fastest-growing regional market for home infusion therapy, driven by the rising prevalence of chronic diseases, expanding healthcare needs, and increasing demand for cost-effective and patient-centric care delivery models. A key driver is the sharp increase in conditions such as diabetes, cancer, and cardiovascular disorders, which often require long-term injectable or intravenous therapies. As healthcare systems in the region face growing patient volumes, home infusion therapy is emerging as a practical alternative to hospital-based care by reducing congestion in healthcare facilities and improving patient convenience. According to India Today, India is projected to have nearly 98 million diabetes cases by 2030, significantly increasing the need for long-term management solutions, including infusion-based treatments.

The market is also being supported by investments in healthcare infrastructure, training, and medical device manufacturing across the region. For example, Becton Dickinson (BD) collaborated with the Infusion Nurses Society India to launch INSPIRE, a national program aimed at improving IV-line safety practices and enhancing nursing competencies—both critical for the safe expansion of home infusion services. In addition, the Yamuna Expressway Industrial Development Authority (YEIDA) is developing a Japanese medical-device cluster near Noida Airport in collaboration with Japanese firms (October 2025), which is expected to strengthen local manufacturing capabilities and improve access to advanced infusion technologies. These developments, combined with rising disease burden and growing healthcare awareness, are driving strong growth in the Asia-Pacific home infusion therapy market.

South America Home Infusion Therapy Market: Rising Demand for Cost-Effective Alternatives to Prolonged Hospital Care

The home infusion therapy market in South America is growing due to the increasing prevalence of chronic diseases, expanding access to healthcare, and rising demand for cost-effective alternatives to prolonged hospital care. Countries across the region are investing in healthcare infrastructure and home-based care models to reduce hospital overcrowding, lower treatment costs, and improve patient outcomes for conditions such as cancer, diabetes, infectious diseases, and autoimmune disorders that require long-term infusion therapy. In addition, an aging population, improving reimbursement frameworks, and greater availability of portable infusion devices are encouraging the adoption of home infusion services. Healthcare providers are increasingly shifting appropriate patients from inpatient settings to home-based treatment, where infusion therapies can be administered safely and conveniently, enhancing quality of life while reducing the burden on healthcare systems. These factors are collectively driving the steady growth of the home infusion therapy market across South America.

Middle East and Africa Market: Increasing Government Support for Home Healthcare Services

The home infusion therapy market in Saudi Arabia is growing due to increasing government support for home healthcare services, rising demand for patient-centric care, and the expansion of chronic disease management programs that reduce the need for hospital visits. As the country modernizes its healthcare system and focuses on improving quality of life under broader healthcare transformation initiatives, home-based treatment is becoming a key strategy to enhance efficiency, reduce hospital congestion, and provide more accessible care for patients with long-term medical needs. The growing prevalence of chronic conditions such as diabetes, cardiovascular diseases, and post-surgical care requirements is further accelerating the adoption of home infusion services across the Kingdom.

A major driver of this growth is the expansion of structured home healthcare programs led by the government. In January 2025, the Saudi Ministry of Health, through regional health clusters, continued to expand home healthcare services nationwide to improve patient experience and deliver comprehensive treatment solutions. These services include intravenous therapy, wound and chronic disease management, post-operative care, and newly introduced offerings such as dialysis, palliative care, and maternal and childcare support. This broadening scope of home-based medical services is strengthening the infrastructure for home infusion therapy and driving its adoption across Saudi Arabia.

Key Developments

·         In April 2026, Soleo Health launched SoleoRare™, a dedicated rare disease specialty pharmacy focused on complex patient needs. The initiative integrated specialized clinical, patient support, and commercial teams to deliver clinician-led, patient-centered care for rare and ultra-rare disease populations.

·         In June 2026, WeInfuse and Eitan Medical announced a software integration to connect smart pumps (such as the Sapphire and Avoset platforms) with clinical workflows. This allows home infusion providers to perform bidirectional data exchange, reducing manual documentation and remote monitoring.

·         In April 2025, McKesson introduced “Specialty and Infusion for Health Systems,” a customized suite designed to support hospitals in building, expanding, and optimizing specialty pharmacy and infusion services. The offering spans fully managed solutions to advisory support, with a focus on enhancing patient outcomes, improving satisfaction, and strengthening retention within the health system’s existing infrastructure.